Jenburkt Pharmaceuticals Ltd. (BSE: 524731) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹404 Cr, it ranks #2,120 by market cap among the 6,137 Indian listed companies on FinBizNet, and #6 of 9 in Non-Prescription Drugs. At ₹870.95 (as of 25 Oct 2026), the share price is 18.9% below its 52-week high of ₹1,073.90 and 2.5% above its 52-week low of ₹850.00. The share price is down 11.8% over one year and down 13.0% over three months.
| Current Price | ₹870.95 |
|---|---|
| Market Cap | ₹404 Cr |
| BSE Code | 524731 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 11.7 |
| Return on Equity | 18.84% |
| Return on Assets | 12.59% |
| 52-Week Range | ₹850.00 – ₹1,073.90 |
| 1-Year Price Change | -11.8% |
| 3-Month Price Change | -13.0% |
| Beta (1Y) | 0.31 |
| Dividend Yield | 2.25% |
| Headquarters | Mumbai, Maharashtra |
| Website | jenburkt.com |
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. It serves its products through stockists, doctors, pharmacies, chemists, large government, semi-government i
1. Pharmaceuticals Business-This segment offers pharmaceutical formulations.
1. Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹43,456 Cr | 40.8 | 48.91% | ₹938 Cr | -11.7% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹15,518 Cr | 23 | 12.36% | ₹2,150 Cr | -18.6% |
| Bliss Gvs Pharma Ltd. | ₹7,005 Cr | 52.5 | 11.60% | ₹286 Cr | +308.7% |
| Zota Health Care Ltd | ₹4,881 Cr | -60.3 | -16.05% | ₹174 Cr | -17.5% |
| Amrutanjan Health Care Ltd. | ₹1,482 Cr | 25.6 | 16.62% | ₹103 Cr | -30.3% |
| Jenburkt Pharmaceuticals Ltd. | ₹404 Cr | 11.7 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹210 Cr | 12.3 | — | — | — |
| Vista Pharmaceuticals Ltd. | ₹39 Cr | -7.9 | -10.82% | — | -37.7% |
| Welcure Drugs & Pharmaceuticals | ₹25 Cr | -5 | -5.50% | — | -75.6% |
Listed by market capitalisation. Ratios are shown for context only.
Jenburkt Pharmaceuticals Ltd. is trading at ₹870.95, with a market capitalisation of ₹404 Cr.
Jenburkt Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Jenburkt Pharmaceuticals Ltd. has a P/E of 11.7 and a return on equity of 18.84%.
Jenburkt Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524731.
Jenburkt Pharmaceuticals Ltd.'s share price is down 11.8% over one year and down 13.0% over three months. Its 52-week range is ₹850.00 to ₹1,073.90.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.